Shenzhen - Delayed Quote CNY

Wuhan Hiteck Biological Pharma Co.,Ltd (300683.SZ)

Compare
28.20 +0.76 (+2.77%)
At close: 3:04 PM GMT+8
Loading Chart for 300683.SZ
DELL
  • Previous Close 27.44
  • Open 28.15
  • Bid 28.26 x --
  • Ask 28.30 x --
  • Day's Range 27.24 - 28.56
  • 52 Week Range 18.80 - 38.37
  • Volume 1,720,300
  • Avg. Volume 2,131,672
  • Market Cap (intraday) 3.691B
  • Beta (5Y Monthly) -0.33
  • PE Ratio (TTM) --
  • EPS (TTM) -1.02
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jul 1, 2020
  • 1y Target Est --

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products includes Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock; aciclovir dispersible tablets for the treatment of genital herpes virus infection, herpes zoster, and immune deficiency chickenpox; indometacin and furazolidone suppositories for internal and external hemorrhoids, anal swelling, fistula, and other anorectal diseases; tinidazole suppositories for trichomonas vaginitis and bacterial vaginosis; nimodipine sustained release tablets for ischemic cerebrovascular disease, migraine, and cerebral vasospasm; trimetazidine dihydrochloride tablets for treatment of stable angina; and azithromycin granules for treatment of acute pharyngitis, tonsillitis, and bronchitis. The company also provides measles and rubella virus nucleic acid detection kit; isolation and identification tube and kit for mycoplasma; and bacterial vaginosis (BV) rapid test kit, as well as diagnostic kit for novel coronavirus N-Protein. In addition, it offers diagnostic kits for IgG antibody to measles virus, hydatid, toxoplasma, rubella virus, cytomegalo virus, and herpes simplex virus I/II; diagnostic kits for IgM antibody to measles virus, herpes simplex virus I/II, cytomegalo virus, rubella virus, and toxoplasma; and diagnostic kit for a –Thalassemia. Further, the company provides Lopinavir and Ritonavir APIs; and intermediates. It offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.

www.hiteck.com.cn

1,520

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 300683.SZ

View More

Performance Overview: 300683.SZ

Trailing total returns as of 11/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

300683.SZ
21.91%
SSE Composite Index
9.57%

1-Year Return

300683.SZ
23.14%
SSE Composite Index
7.19%

3-Year Return

300683.SZ
43.85%
SSE Composite Index
9.05%

5-Year Return

300683.SZ
1.19%
SSE Composite Index
12.17%

Compare To: 300683.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300683.SZ

View More

Valuation Measures

Annual
As of 11/25/2024
  • Market Cap

    3.59B

  • Enterprise Value

    2.77B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.02

  • Price/Book (mrq)

    1.47

  • Enterprise Value/Revenue

    4.50

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -21.82%

  • Return on Assets (ttm)

    -3.45%

  • Return on Equity (ttm)

    -5.58%

  • Revenue (ttm)

    614.85M

  • Net Income Avi to Common (ttm)

    -134.13M

  • Diluted EPS (ttm)

    -1.02

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    877.57M

  • Total Debt/Equity (mrq)

    2.13%

  • Levered Free Cash Flow (ttm)

    -59.21M

Research Analysis: 300683.SZ

View More

Company Insights: 300683.SZ

Research Reports: 300683.SZ

View More

People Also Watch